Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai gained its first U.S. approval for one of its in-house developed oncology products, Halaven (eribulin), but the company's blockbuster expectations may be tempered by progression-free survival data that did not meet secondary endpoints
You may also be interested in...
Business And Finance News, In Brief
Study Finds Personalized Medicine Increasingly Emphasized In Oncology
Business And Finance News, In Brief
Study Finds Personalized Medicine Increasingly Emphasized In Oncology
Eisai Rides High On Expanded Oncology Capabilities, Enters Neglected Disease Foray
TOKYO - Two days after gaining U.S. FDA approval for its first in-house produced oncology product, Eisai continued its week of "firsts" with the announcement that it is the first Japanese pharmaceutical company to reach a supply agreement with the World Health Organization to combat a neglected tropical disease